Stay updated with breaking news from Sciences Ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Roivant Sciences (NASDAQ:ROIV – Get Free Report)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a report issued on Monday, Benzinga reports. They presently have a $18.00 target price on the stock. HC Wainwright’s price target indicates a potential upside of 64.53% from the company’s previous close. Other research analysts […]
Roivant Sciences (NASDAQ:ROIV – Free Report) had its price objective increased by Deutsche Bank Aktiengesellschaft from $14.00 to $15.00 in a report released on Wednesday, Benzinga reports. They currently have a buy rating on the stock. ROIV has been the subject of several other reports. Piper Sandler started coverage on Roivant Sciences in a research […]
Roivant Sciences (NASDAQ:ROIV – Free Report) had its price target upped by HC Wainwright from $17.00 to $18.00 in a research note released on Wednesday morning, Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Roivant Sciences’ Q1 2025 earnings at ($0.25) EPS, Q2 2025 earnings […]
VANCOUVER, BC, April 2, 2024 /CNW/ - Filament Health Corp. , a clinical-stage natural psychedelic drug development company, released its fourth quarter financial results and operational highlights...
Detailed price information for Lennar Corp (LEN-N) from The Globe and Mail including charting and trades.